Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Antiinflammatory C5a receptor blocker enters clinical testing

Sep. 28, 2001

Inhibitors of cytokine production under development by Hokuriku Seiyaku

Sep. 27, 2001

UR-8880 exerts potent antiinflammatory effects in the absence of GI toxicity

Sep. 27, 2001

Preclinical profile of ML-3000, a new COX/5-LO inhibitor, discussed at Inflammation 2001

Sep. 27, 2001

FibroGen describes new compounds for fibrotic disorders

Sep. 26, 2001

Potential of Ono-4817 in osteoarthritis Rx discussed in Edinburgh

Sep. 26, 2001

Vertex to focus on development of second-generation p38 MAP kinase inhibitors

Sep. 26, 2001

Orally active antiinflammatory agents from Pharmacia selectively inhibit COX-2

Sep. 25, 2001

Orally active IKK2 inhibitor characterized at Inflammation 2001

Sep. 25, 2001

Clinical candidate p38 MAP kinase inhibitor selected by Boehringer Ingelheim

Sep. 25, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...